Caris Life Sciences, Inc. Common Stock (CAI) - Net Assets
Based on the latest financial reports, Caris Life Sciences, Inc. Common Stock (CAI) has net assets worth $593.49 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.16 Billion) and total liabilities ($568.90 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore Caris Life Sciences, Inc. Common Stock cash flow conversion to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $593.49 Million |
| % of Total Assets | 51.06% |
| Annual Growth Rate | 17.98% |
| 5-Year Change | -17.79% |
| 10-Year Change | 25.16% |
| Growth Volatility | 120.82 |
Caris Life Sciences, Inc. Common Stock - Net Assets Trend (2003–2025)
This chart illustrates how Caris Life Sciences, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Caris Life Sciences, Inc. Common Stock for the complete picture of this company's asset base.
Annual Net Assets for Caris Life Sciences, Inc. Common Stock (2003–2025)
The table below shows the annual net assets of Caris Life Sciences, Inc. Common Stock from 2003 to 2025. For live valuation and market cap data, see how much is Caris Life Sciences, Inc. Common Stock worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $577.31 Million | +123.10% |
| 2024-12-31 | $-2.50 Billion | -16.50% |
| 2023-12-31 | $-2.14 Billion | -26.02% |
| 2022-12-31 | $-1.70 Billion | -342.38% |
| 2020-12-31 | $702.24 Million | +1.30% |
| 2019-12-31 | $693.24 Million | -1.13% |
| 2018-12-31 | $701.13 Million | +24.35% |
| 2017-12-31 | $563.85 Million | +23.24% |
| 2016-12-31 | $457.50 Million | -0.81% |
| 2015-12-31 | $461.26 Million | +4.14% |
| 2014-12-31 | $442.90 Million | +6.69% |
| 2013-12-31 | $415.13 Million | +19.69% |
| 2012-12-31 | $346.85 Million | +39.44% |
| 2011-12-31 | $248.74 Million | +25.83% |
| 2010-12-31 | $197.67 Million | +53.12% |
| 2009-12-31 | $129.10 Million | +13.45% |
| 2008-12-31 | $113.79 Million | -13.24% |
| 2007-12-31 | $131.15 Million | +372.52% |
| 2006-12-31 | $27.75 Million | -15.88% |
| 2005-12-31 | $32.99 Million | +38.51% |
| 2004-12-31 | $23.82 Million | +56.95% |
| 2003-12-31 | $15.18 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Caris Life Sciences, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 254873600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $283.00K | 0.05% |
| Other Comprehensive Income | $936.00K | 0.16% |
| Other Components | $3.12 Billion | 541.28% |
| Total Equity | $577.31 Million | 100.00% |
Caris Life Sciences, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Caris Life Sciences, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Seaboard Corporation
NYSE MKT:SEB
|
$4.35 Billion |
|
Faw Car Co Ltd
SHE:000800
|
$4.35 Billion |
|
Alaska Air Group Inc
NYSE:ALK
|
$4.35 Billion |
|
Frontdoor Inc
NASDAQ:FTDR
|
$4.35 Billion |
|
SentinelOne Inc
NYSE:S
|
$4.35 Billion |
|
Acter Co Ltd
TWO:5536
|
$4.34 Billion |
|
Duolingo Inc
NASDAQ:DUOL
|
$4.34 Billion |
|
CommScope Holding Co Inc
NASDAQ:COMM
|
$4.34 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Caris Life Sciences, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -2,498,838,000 to 577,307,000, a change of 3,076,145,000.
- Net loss of 537,957,000 reduced equity.
- Share repurchases of 113,000 reduced equity.
- New share issuances of 649,697,000 increased equity.
- Other comprehensive income increased equity by 726,000.
- Other factors increased equity by 2,963,792,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-537.96 Million | -93.18% |
| Share Repurchases | $113.00K | -0.02% |
| Share Issuances | $649.70 Million | +112.54% |
| Other Comprehensive Income | $726.00K | +0.13% |
| Other Changes | $2.96 Billion | +513.38% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Caris Life Sciences, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 44.55x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 21.45x to 44.55x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-12-31 | $0.72 | $15.38 | x |
| 2004-12-31 | $1.13 | $15.38 | x |
| 2005-12-31 | $1.56 | $15.38 | x |
| 2006-12-31 | $1.31 | $15.38 | x |
| 2007-12-31 | $7.86 | $15.38 | x |
| 2008-12-31 | $6.54 | $15.38 | x |
| 2009-12-31 | $7.21 | $15.38 | x |
| 2010-12-31 | $9.87 | $15.38 | x |
| 2011-12-31 | $11.68 | $15.38 | x |
| 2012-12-31 | $17.39 | $15.38 | x |
| 2013-12-31 | $18.28 | $15.38 | x |
| 2014-12-31 | $20.90 | $15.38 | x |
| 2015-12-31 | $21.93 | $15.38 | x |
| 2016-12-31 | $23.59 | $15.38 | x |
| 2017-12-31 | $28.76 | $15.38 | x |
| 2018-12-31 | $35.38 | $15.38 | x |
| 2019-12-31 | $38.49 | $15.38 | x |
| 2020-12-31 | $39.12 | $15.38 | x |
| 2022-12-31 | $-6.68 | $15.38 | x |
| 2023-12-31 | $-8.42 | $15.38 | x |
| 2024-12-31 | $-9.81 | $15.38 | x |
| 2025-12-31 | $0.35 | $15.38 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Caris Life Sciences, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -93.18%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -66.25%
- • Asset Turnover: 0.72x
- • Equity Multiplier: 1.95x
- Recent ROE (-93.18%) is below the historical average (4.69%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | -17.45% | -5.51% | 0.25x | 12.72x | $-4.17 Million |
| 2004 | 38.74% | 13.84% | 0.37x | 7.64x | $6.85 Million |
| 2005 | 30.27% | 16.22% | 0.34x | 5.48x | $6.69 Million |
| 2006 | 18.85% | 28.12% | 0.07x | 10.20x | $2.46 Million |
| 2007 | 14.67% | 29.65% | 0.18x | 2.74x | $6.12 Million |
| 2008 | -23.69% | -32.42% | 0.20x | 3.63x | $-38.33 Million |
| 2009 | 10.50% | 20.77% | 0.17x | 2.90x | $646.20K |
| 2010 | 15.80% | 36.44% | 0.13x | 3.42x | $10.42 Million |
| 2011 | 21.82% | 39.93% | 0.13x | 4.14x | $27.19 Million |
| 2012 | 18.30% | 36.49% | 0.13x | 4.00x | $28.78 Million |
| 2013 | 15.42% | 30.10% | 0.13x | 4.04x | $22.47 Million |
| 2014 | 13.63% | 26.48% | 0.13x | 4.06x | $16.06 Million |
| 2015 | 5.83% | 10.75% | 0.13x | 4.32x | $-19.20 Million |
| 2016 | 1.31% | 2.04% | 0.14x | 4.49x | $-39.75 Million |
| 2017 | 12.78% | 20.68% | 0.14x | 4.31x | $15.68 Million |
| 2018 | 11.21% | 18.19% | 0.14x | 4.30x | $8.48 Million |
| 2019 | 4.47% | 7.44% | 0.14x | 4.19x | $-38.31 Million |
| 2020 | 3.95% | 9.43% | 0.11x | 3.72x | $-42.49 Million |
| 2022 | 0.00% | -124.12% | 0.36x | 0.00x | $-150.62 Million |
| 2023 | 0.00% | -111.53% | 0.74x | 0.00x | $-126.92 Million |
| 2024 | 0.00% | -68.38% | 1.20x | 0.00x | $-32.01 Million |
| 2025 | -93.18% | -66.25% | 0.72x | 1.95x | $-595.69 Million |
Industry Comparison
This section compares Caris Life Sciences, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,677,567
- Average return on equity (ROE) among peers: -58.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Caris Life Sciences, Inc. Common Stock (CAI) | $593.49 Million | -17.45% | 0.96x | $4.35 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $86.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.60 Billion |
| Abeona Therapeutics Inc (ABEO) | $42.37 Million | -200.47% | 0.88x | $323.66 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $183.46 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $804.47 Million |
| Arbutus Biopharma Corp (ABUS) | $203.00 Million | -189.21% | 0.36x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $60.67K | -43.96% | 0.04x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $56.72 Million | -25.23% | 0.07x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-52.67 Million | 0.00% | 0.00x | $3.63 Billion |
About Caris Life Sciences, Inc. Common Stock
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exom… Read more